Arctic Vision to Acquire MDCO Technology’s Ophthalmic Device Business, Forming a Global Drug-Device Innovation Platform
Shanghai, February 2, 2026 — Arctic Vision (Cayman) Limited, a leading global player in ophthalmology headquartered in Shanghai, announced today that it has entered into a strategic agreement to acquire the ophthalmic device business of MDCO Technology, an innovative ophthalmic medical-device company based in Hangzhou. This move aims to create an integrated global platform combining cutting-edge drug and device innovations in eye care.
Strengthening Global Ophthalmic Innovation
The acquisition will bring MDCO’s advanced portfolio of premium intraocular lenses (IOLs), implantable contact lenses (Phakic Lens), and refractive device technologies into Arctic Vision’s existing framework for ophthalmic innovation. By integrating MDCO’s specialized device engineering and manufacturing capabilities with Arctic Vision’s pharmaceutical research and development, the company intends to bolster its ability to develop comprehensive solutions targeting a range of ocular conditions.
This strategic alignment supports Arctic Vision’s long-term growth plan by expanding its pipeline with novel therapeutic technologies addressing high unmet medical needs in eye diseases. The combined expertise will enhance Arctic Vision’s focus across key areas including retinal diseases, ocular surface disorders, and neuro-ophthalmology, while leveraging MDCO’s proficiency in premium lens design and production.
Operational Footprint and Integration
Per the terms of the agreement, MDCO will become a wholly owned subsidiary of Arctic Vision. Core operations will be maintained at three main sites: Shanghai (focusing on biopharmaceutical R&D, regulatory affairs, and operations), Hangzhou (specializing in implanted device R&D, manufacturing, and commercial management), and California (handling design and fostering global partnerships). This tri-regional structure reflects the company’s commitment to harnessing global talent and resources to accelerate innovation and commercialization.
Leadership Statements
Dr. Eddy Wu, Founder, Chairman and CEO of Arctic Vision, emphasized the strategic importance of the acquisition:
"This transaction represents a pivotal step for Arctic Vision’s long-term growth strategy. Through the integration of MDCO’s ophthalmic device platforms with Arctic Vision’s pharmaceutical innovation capabilities, we are establishing a truly comprehensive ophthalmic innovation ecosystem—one that integrates scientific excellence with advanced manufacturing and commercial scale. Looking ahead, we are building a company structurally prepared for broader global investment participation and future capital-market opportunities, while expanding our ability to reach more patients and deliver greater impact across the ophthalmology community worldwide."
Similarly, Mr. Liang Liu, Chairman of MDCO Technology, expressed optimism about joining the Arctic Vision platform:
"Becoming part of Arctic Vision’s integrated platform opens a new chapter for MDCO. MDCO’s hallmark intraocular and refractive products will benefit from Arctic Vision’s strong R&D and regulatory foundation, enabling accelerated development and broader market access worldwide."
About Arctic Vision
Arctic Vision is a Shanghai-based global ophthalmic innovation company dedicated to developing next-generation therapies in retinal diseases, dry eye conditions, and ocular neuroprotection. With operations that extend to Hong Kong and the United States, Arctic Vision leverages both in-house R&D platforms and strategic collaborations to advance treatments from early discovery through commercialization.
About MDCO Technology
MDCO Technology Co., Ltd. specializes in ophthalmic medical devices, particularly intraocular and refractive lens systems. The company has research, development, and manufacturing facilities in Hangzhou, China, and California, USA. With nearly two decades of expertise in material science and precision molding, MDCO’s focus is on premium cataract and myopia correction lenses and intelligent manufacturing innovations in surgical platforms.
This announcement includes forward-looking statements that involve risks and uncertainties, including the ability to complete the transaction, integrate operations, secure regulatory approvals, and realize anticipated synergies. Actual results may vary.
For further information, the companies may be contacted at:
Arctic Vision – Corporate Communications
Email: [email protected]
MDCO Technology – Investor Relations
Email: [email protected]
Published by The Manila Times on February 2, 2026
